Neo Ivy Capital Management’s Sage Therapeutics SAGE Stock Holding History

Neo Ivy Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,290	Closed	-$484K	–	440
2023 Q2	$484K	Buy	+10,290	New	+$512K	0.26%	128
2022 Q4	$194K	Buy	+5,094	New	+$195K	0.13%	230
2021 Q3	–	Sell	-2,045	Closed	-$116K	–	611
2021 Q2	$116K	Buy	+2,045	New	+$145K	0.12%	242
2021 Q1	–	Sell	-1,434	Closed	-$124K	–	607
2020 Q4	$124K	Sell	1,434 -2,861	-67%	-$211K	0.14%	227
2020 Q3	$262K	Buy	+4,295	New	+$218K	0.27%	138

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neo Ivy Capital Management's SAGE Position: Q3 2023 in Review

Neo Ivy Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 10,290 shares — an estimated $484K sold.

Neo Ivy Capital Management first reported a position in SAGE in Q3 2020 and held it in 5 quarters. The position peaked at $484K in Q2 2023. 193 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

Neo Ivy Capital Management reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
Neo Ivy Capital Management sold 10,290 Sage Therapeutics shares in Q3 2023, an estimated $484K.
Neo Ivy Capital Management first reported a position in Sage Therapeutics in Q3 2020 and held it in 5 quarters.
Neo Ivy Capital Management's Sage Therapeutics position peaked at $484K in Q2 2023.
193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Neo Ivy Capital Management's 13F filing for Q3 2023, filed 30 Nov 2023.